within Pharmacolibrary.Drugs.ATC.A;

model A07EC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2250 / 1000000,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Balsalazide is an anti-inflammatory drug belonging to the class of aminosalicylates, used primarily in the treatment of mild-to-moderate ulcerative colitis. It is a prodrug that releases mesalazine (5-aminosalicylic acid, 5-ASA) in the colon. Balsalazide is approved for use in the United States and certain other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sandborn, WJ, et al., &amp; Buch, A (2004). Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. <i>Alimentary pharmacology &amp; therapeutics</i> 19(10) 1089–1098. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2036.2004.01964.x&quot;>10.1111/j.1365-2036.2004.01964.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15142198/&quot;>https://pubmed.ncbi.nlm.nih.gov/15142198</a></p></li><li><p>Muijsers, RB, &amp; Goa, KL (2002). Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. <i>Drugs</i> 62(11) 1689–1705. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262110-00010&quot;>10.2165/00003495-200262110-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12109930/&quot;>https://pubmed.ncbi.nlm.nih.gov/12109930</a></p></li><li><p>Tursi, A (2009). Balsalazide in treating colonic diseases. <i>Expert opinion on drug metabolism &amp; toxicology</i> 5(12) 1555–1563. DOI:<a href=&quot;https://doi.org/10.1517/17425250903228842&quot;>10.1517/17425250903228842</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19708827/&quot;>https://pubmed.ncbi.nlm.nih.gov/19708827</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07EC04;
